Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS: HLA-Mismatched Unrelated Donor HCT With PTCy for Hematologic Malignancies
NCT04904588Phase 2Active, not recruiting
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- Sep 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), sponsored by Center for International Blood and Marrow Transplant Research. Started Sep 2021; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04904588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904588.